No medical breakthrough can bypass the physical limits of real-world clinical logistics.
Even when therapeutic and diagnostic innovations secure regulatory clearance, their real-world impact is severely throttled by institutional bureaucracy, staffing shortages, and funding gaps.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
This illustrates that despite rapid, landmark regulatory approvals, gene therapies are constrained by severe and intense real-world physical and clinical logistics.
This shows that even a landmark gene therapy requires a complex, multi-site network of specialized medical centers to bypass high-intensity physical logistics.
Even a highly advanced oncology screening breakthrough cannot be deployed at scale if it threatens to overwhelm the physical and operational capacity of local clinical systems.